Consultant

Dr Deborah Enting

Consultant Medical Oncologist
Msc, MRCP, MBBS
Profile Photo for Deborah Enting

Deborah Enting is a Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust, and an Honorary Senior Lecturer at King's College London.

Oncology
Dutch, English
In-person, Phone call, Video call
From £350

Bio

Dr Enting specialises in the treatment of Urological Cancers and the systemic treatment (chemotherapy, immunotherapy and targeted therapies) for Bladder, Prostate, Kidney and Testicular cancers.

Dr Enting undertook her medical training at the University of Groningen in The Netherlands and trained in Medical Oncology at Guy's and St George's Hospitals. She was a research fellow at the Department of Immunobiology at King's College London and in collaboration with colleagues of the Translational Oncology Urology Research (TOUR) group at King’s College London she works on tumour immune surveillance and bladder cancer research. 

She is national lead on a number of clinical trials including the IRONMAN study, an international registry for men with Prostate cancer.

More information

  • Consultant Medical Oncologist
    Guy’s and St Thomas’ NHS Foundation Trust
     

•    MSc (2002) 
•    Arts Examen (‘MBBS’ equivalent) (2003)
•    MRCP (2007) 
•    Speciality Certificate Examination Medical Oncology (2011)
•    Postgraduate Diploma Oncology (2012)
•    CCT Medical Oncology (2017)

  • Chemotherapy
  • Immune therapy
  • Targeted therapy for patients with urological cancers
  • Kidney Cancer
  • Testicular Cancer

  • Fellow of Royal College of Physicians 2022

  • So A, Karampera C, Khan M, Russell B, Moss C, Monroy-Iglesias MJ, Thillai K, Josephs D, Pintus E, Rudman S, Van Hemelrijck M, Dolly S, Enting D. Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19. BMC Urol 2022: [Epub ahead of print]
  • Soualhi A, Rammant E, George G, Russell B, Enting D, Nair R, Van Hemelrijck M, Bosco C. The incidence and prevalence of upper tract urothelial carcinoma: a systemic review. BMC Urol 2021;21: [Epub ahead of print]
  • Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 2021;384:2102-2114
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G, Light M, Whitehead A, Ellis D, Sarwar N, Enting D, Birtle A, Johnson B, Huddart R, Griffiths G. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). Clin Cancer Res 2021;27:1882-1892
  • Abdul-Jawad S, Baù L, Alaguthurai T, Del Molino Del Barrio I, Laing AG, Hayday TS, Monin L, Muñoz-Ruiz M, McDonald L, Francos Quijorna I, McKenzie D, Davis R, Lorenc A, Chan JNE, Ryan S, Bugallo-Blanco E, Yorke R, Kamdar S, Fish M, Zlatareva I, Vantourout P, Jennings A, Gee S, Doores K, Bailey K, Hazell S, De Naurois J, Moss C, Russell B, Khan AA, Rowley M, Benjamin R, Enting D, Alrifai D, Wu Y, Zhou Y, Barber P, Ng T, Spicer J, Van Hemelrijck M, Kumar M, Vidler J, Lwin Y, Fields P, Karagiannis SN, Coolen ACC, Rigg A, Papa S, Hayday AC, Patten PEM, Irshad S. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell. 2021;39:257-275
  • Russell B, Moss CL, Shah V, Ko TK, Palmer K, Sylva R, George G, Monroy-Iglesias MJ, Patten P, Ceesay MM, Benjamin R, Potter V, Pagliuca A, Papa S, Irshad S, Ross P, Spicer J, Kordasti S, Crawley D, Wylie H, Cahill F, Haire A, Zaki K, Sita-Lumsden A, Josephs D, Enting D, Swampillai A, Sawyer E, D'Souza A, Gomberg S, Harrison C, Fields P, Wrench D, Rigg A, Sullivan R, Kulasekararaj A; Guy’s Cancer Real World Evidence, Dolly S, Van Hemelrijck M. Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London. Br J Cancer 2021; [Epub ahead of print]
  • So ACP, McGrath H, Ting J, Srikandarajah K, Germanou S, Moss C, Russell B, Monroy-Iglesias M, Dolly S, Irshad S, Van Hemelrijck M, Enting D. COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers, Published Online July 2021
  • Bessa A, Rammant E, Enting D, Bryan RT, Shamim Khan M, Malde S, Nair R, Thurairaja R, Cahill F, Amery S, Smith S, Ahmed K, Russell B, Moss C, Chatterton K, Häggström C, Van Hemelrijck M. The Need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature. PLoS One 2021;16: [Epub ahead of print]
  • Chau C, Rimmer Y, Choudhury A, Leaning D, Law A, Enting D, Lim JH, Hafeez S, Khoo V, Huddart R, Mitchell D, Henderson DR, McGrane J, Beresford M, Vasudev N, Beesley S, Hilman S, Manetta C, Sriram R, Sharma A, Eswar C, Treece S, Vilarino-Varela M, Varughese M, Glen PhD H, Pintus E, Crabb S. Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results from a UK Patient Retrospective Cohort Study. Int J Radiat Oncol Biol Phys 2021;110:1143-1150
  •  
  • Russell B, Moss CL, Palmer K, Sylva R, D'Souza A, Wylie H, Haire A, Cahill F, Steel R, Hoyes A, Wilson I, Macneil A, Shifa B, Monroy-Iglesias MJ, Papa S, Irshad S, Ross P, Spicer J, Kordasti S, Crawley D, Zaki K, Sita-Lumsden A, Josephs D, Enting D, Swampillai A, Sawyer E, Fields P, Wrench D, Rigg A, Sullivan R, Van Hemelrijck M, Dolly S. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients. Cancers 2021;13 [Epub ahead of print]
  • Mannion L, Bosco C, Nair R, Mullassery V, Enting D, Jones EL, Van Hemelrijck M, Hughes S. Overall survival, disease-specific survival and local recurrence outcomes in patients with muscle-invasive bladder cancer treated with external beam radiotherapy and brachytherapy: a systematic review. BJU Int 2020;125:780-791 
  • Bessa A, Martin R, Häggström C, Enting D, Amery S, Khan MS, Cahill F, Wylie H, Broadhead S, Chatterton K, Malde S, Nair R, Thurairaja R, Kumar P, Haire A, Green S, Northover M, Briggs K, Van Hemelrijck M. Unmet needs in sexual health in bladder cancer patients: a systematic review of the evidence. BMC Urol 2020;20:64
  • Russell B, Moss C, Papa S, Irshad S, Ross P, Spicer J, Kordasti S, Crawley D, Wylie H, Cahill F, Haire A, Zaki K, Rahman F, Sita-Lumsden A, Josephs D, Enting D, Lei M, Ghosh S, Harrison C, Swampillai A, Sawyer E, D'Souza A, Gomberg S, Fields P, Wrench D, Raj K, Gleeson M, Bailey K, Dillon R, Streetly M, Rigg A, Sullivan R, Dolly S, Van Hemelrijck M. Factors Affecting COVID-19 Outcomes in Cancer Patients: A first Report from Guy’s Cancer Centre in London. Front Oncol 2020;10:1279
  • Kotecha P, Moss CL, Enting D, Gillett C, Joseph M, Josephs D, Rudman S, Hughes S, Cahill F, Wylie H, Haire A, Rosekilly J, Khan MS, Nair R, Thurairaja R, Malde S, Van Hemelrijck M. Cohort Profile: King’s Health Partner bladder cancer biobank. BMC Cancer 2020;20:920 [Epub ahead of print]
  • Moss C, Haire A, Cahill F, Enting D, Hughes S, Smith D, Sawyer E, Davies A, Zylstra J, Haire K, Rigg A, Van Hemelrijck M. Guy’s Cancer Cohort – real world evidence for cancer pathways. BMC Cancer 2020;20:187 [Epub ahead of print]
  • Joseph M, Enting D. Immune Responses in Bladder Cancer – Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. Front Oncol 2019;9:1270
  • Bessa A, Maclennan S, Enting D, Bryan B, Jospehs D, Hughes S, Amery S, Khan MS, Malde S, Nair R, Cahill F, Wylie H, Thurairaja R, Chatterton K, Kinsella N, Haggstrom C, Van Hemelrijck M. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol, 2019 Jan 31 [Epub ahead of print] 
  • Wylie H, Cahill F, Santaolalla A, Moss CL, Enting D, Amery S, Chatterton K, Khan MS, Bryan RT, Gillett C, Josephs D, Chowdhury S, Rudman S, Hughes S, Relton C, Van Hemelrijck M. Graham Roberts Study protocol: first ‘trials within cohort study’ for bladder cancer. BMJ Open 2019;9:e029468
  • Saifuddin S, Devlies W, Santaolalla A, Cahill F, George G, Enting D, Rudman S, Cathcart P, Challacombe B, Dasgupta P, Galustian C, Chandra A, Chowdhury S, Gillett C, Van Hemelrijck M. King’s Health Partners’ Prostate Cancer Biobank (KHP PCaBB). BMC Cancer, 2017;17:784
Share

Contact us

Request an appointment with our world-leading consultants today, or speak to our helpful advisors for tailored advice.